A Message From Our Program Leader
Multiple myeloma has undergone a revolution of treatment in the last decade that has resulted in patients living longer with this disease and indeed living better. We are now for the first time genuinely speaking about a potential cure. At HonorHealth we are at the cutting edge of myeloma providing expert consultation along with all of the novel therapies that have changed this disease. We have an extensive portfolio of clinical trials so patients can have the most options possible. We are honored to serve the community by providing world class care in a compassionate manner so patients with myeloma and related diseases can live their best life.
About Our Program
The Plasma Cell Disorders program is comprised of a multi-disciplinary team including physicians, nurse practitioners, pharmacists, nurses and many others to ensure patients receive the best care possible.
We provide consultation with one of the leading experts in myeloma in the world so that patients can understand their disease and clearly discuss treatment options. Some patients remain under the care of their community oncologist with intermittent visits with the myeloma team. Others will have full care here, including support from our bone marrow transplant and cellular therapy teams providing the novel therapies such as CAR T Cell therapy and bispecific antibodies.
We also provide clinical trials that allow us to introduce cutting edge therapies and even more options for patients.
Multiple Myeloma and Plasma Cell Disorders Research Facts and Figures
Myeloma is twice as common in the African American population.
Survival with Myeloma used to be only 2-3 years but now averages over 10 years.
Over 20 drugs have been approved for myeloma over the last 15 years.
The average of diagnosis is 69 but 4-5 years younger in African American and Latino American patients.
